A Phase 4 interventional study of Chlorhexidine and Iodine in Hysterectomy, sponsored by TriHealth Inc.. Terminated at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-11.
Sponsored by TriHealth Inc. · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized controlled trial to determine the influence of chlorhexidine gluconate surgical/topical antiseptic solutions on the bacterial environment of the vagina during hysterectomy and compare that to the effect of standard iodine-based preparations on the same.
Postoperative infection remains the most common complication of surgical procedures in gynecology. Historically, 30-40% of patients undergoing a hysterectomy develop a post-operative infection. The initiation of antibiotic prophylaxis for appropriate surgical procedures was a significant advancement in the prevention of surgical site infection.
Antibiotic prophylaxis has been standardized and universally implemented. A remaining variable is the method of aseptic preparation of the vagina with substantial variation of technique being reported even within institutions.
The most recent Committee Opinion by the American College of Obstetricians and Gynecologists concludes there is insufficient evidence to render a strong recommendation for either povidone-iodine or chlorhexidine as the ideal agent for surgical preparation of the vagina and that further evidence is necessary.
Povidone-iodine solution has been considered the standard for aseptic surgical preparation of the vagina for decades and is the only solution approved by the FDA for vaginal use. There are however specific qualities of the solution that suggest it may be less than ideal for use in the vagina. More contemporary efforts have begun to focus on chlorhexidine as a more ideal agent for aseptic efforts in surgical preparation of the vagina.
The purpose of our study is to use a randomized controlled trial to determine if chlorhexidine gluconate surgical preparation maintains a lower rate of contamination to the surgical field.
TriHealth Inc. is the lead sponsor of 102 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Chlorhexidine
Drug: Iodine
Chlorhexidine preparation solutions
Iodine-based preparation solutions
Number of Participants With Contamination
Contamination is defined as having \>5000 bacteria within a culture
Time frame: 90 minutes from initial preparation
| Milestone | Chlorhexidine Group | Iodine Group |
|---|---|---|
| Started | 47 | 41 |
| Completed | 44 | 41 |
| Not completed | 3 | 0 |
| Withdrew: Incorrect labeling of samples | 2 | 0 |
| Withdrew: Exclusion criteria - patient receiving flagyl for treatment | 1 | 0 |
Contamination is defined as having \>5000 bacteria within a culture
| Participants | Chlorhexidine Group | Iodine Group |
|---|---|---|
| Number of Participants With Contamination | 20 | 35 |
Collected over 2 week post-op. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chlorhexidine Group | 0/44 (0%) | 0/44 (0%) | 0/44 (0%) |
| Iodine Group | 0/41 (0%) | 0/41 (0%) | 0/41 (0%) |
| Age, Continuous(years) | Chlorhexidine Group | Iodine Group | Total |
|---|---|---|---|
| Mean | 57.6 ± 10.9 | 62.2 ± 11.6 | 59.8 ± 11.4 |
| Sex: Female, Male(Participants) | Chlorhexidine Group | Iodine Group | Total |
|---|---|---|---|
| Female | 44 | 41 | 85 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Chlorhexidine Group | Iodine Group | Total |
|---|---|---|---|
| White | 42 | 39 | 81 |
| Black/African American | 2 | 1 | 3 |
| Asian | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Chlorhexidine Group | Iodine Group | Total |
|---|---|---|---|
| United States | 44 | 41 | 85 |
| Bacterial Vaginosis (BV) positive(Participants) | Chlorhexidine Group | Iodine Group | Total |
|---|---|---|---|
| Count of participants | 12 | 18 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2018 to primary completion in Aug 2019, 15 months.
Results were first posted in Nov 2020, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chlorhexidine